PF-08046031 / Pfizer - LARVOL DELTA

A Study to Learn About the Study Medicine Called PF-08046031 in Advanced Melanoma and Other Solid Tumors (clinicaltrials.gov) - P1 | N=11 | Active, not recruiting | Sponsor: Pfizer | Recruiting ➔ Active, not recruiting | N=185 ➔ 11 | Trial completion date: Jun 2030 ➔ Feb 2026 | Trial primary completion date: Jun 2029 ➔ Feb 2026

Enrollment change • Enrollment closed • Trial completion date • Trial primary completion date • Melanoma • Oncology • Solid Tumor

A Study to Learn About the Study Medicine Called PF-08046031 in Advanced Melanoma and Other Solid Tumors (clinicaltrials.gov) - P1 | N=185 | Recruiting | Sponsor: Pfizer | Not yet recruiting ➔ Recruiting

Enrollment open • Melanoma • Oncology • Solid Tumor

PF-08046031: A promising first-in-class antibody-drug conjugate for targeting novel tumor antigen in melanoma (AACR 2025) - "At the highest dose of 6.0 mg/kg, TGI reached 87% for A2058-derived tumors and 90% for COLO853-derived tumors. These findings support the clinical development of PF-08046031 for targeting multiple solid tumors."

Cutaneous Melanoma • Esophageal Cancer • Esophageal Squamous Cell Carcinoma • Head and Neck Cancer • Lung Cancer • Melanoma • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma of Head and Neck • MELTF • MELTF